Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Diabetes

  Free Subscription


Articles published in Kidney Int

Retrieve available abstracts of 69 articles:
HTML format



Single Articles


    March 2024
  1. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    PubMed    


  2. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    PubMed    


  3. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    PubMed     Abstract available


    February 2024
  4. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available


    January 2024
  5. MUTO Y, Humphreys BD
    Leveraging multimodal chromatin profiling to identify a new potential driver of diabetic kidney disease.
    Kidney Int. 2024;105:25-27.
    PubMed     Abstract available


    December 2023
  6. FU EL, Mastrorilli J, Bykov K, Wexler DJ, et al
    A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2023 Dec 13:S0085-2538(23)00865-7. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  7. SOURRIS KC, Ding Y, Maxwell SS, Al-Sharea A, et al
    Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Kidney Int. 2023 Dec 5:S0085-2538(23)00756-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  8. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Erratum to "Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease." Kidney Int. 2023;104:787-802.
    Kidney Int. 2023;104:1228.
    PubMed    


  9. IWAGAMI M
    Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
    Kidney Int. 2023;104:1062-1064.
    PubMed     Abstract available


    November 2023
  10. EUN M, Kim D, Shin SI, Yang HO, et al
    Chromatin accessibility analysis and architectural profiling of human kidneys reveal key cell types and a regulator of diabetic kidney disease.
    Kidney Int. 2023 Nov 2:S0085-2538(23)00757-3. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  11. FANG Z, Lee K, He JC
    A central role for mesangial cells in the initiation of diabetic nephropathy.
    Kidney Int. 2023;104:872-874.
    PubMed    


    October 2023
  12. AZUSHIMA K, Kovalik JP, Yamaji T, Ching J, et al
    Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
    Kidney Int. 2023 Oct 5:S0085-2538(23)00565-3. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


    September 2023
  13. SMERKOUS D, Mauer M, Tondel C, Svarstad E, et al
    Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.
    Kidney Int. 2023 Sep 27:S0085-2538(23)00675-0. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


    August 2023
  14. CHAN KW, Smeijer JD, Schechter M, Jongs N, et al
    Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
    Kidney Int. 2023 Aug 30:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  15. SEN T, Ju W, Nair V, Ladd P, et al
    Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
    Kidney Int. 2023 Aug 3:S0085-2538(23)00537-9. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


    July 2023
  16. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease.
    Kidney Int. 2023 Jul 26:S0085-2538(23)00502-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  17. HONG S, Kim KS, Han K, Park CY, et al
    A cohort study found a high risk of end-stage kidney disease associated with acromegaly.
    Kidney Int. 2023 Jul 23:S0085-2538(23)00501-X. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available


  18. MIMURA I, Nangaku M
    Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes.
    Kidney Int. 2023 Jul 5:S0085-2538(23)00483-0. doi: 10.1016/j.kint.2023.
    PubMed    


  19. HEERSPINK HJL, Jongs N, Neuen BL, Schloemer P, et al
    Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
    Kidney Int. 2023;104:181-188.
    PubMed     Abstract available


    April 2023
  20. CHAPMAN D, Judge PK, Sardell RJ, Staplin N, et al
    Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
    Kidney Int. 2023;103:787-790.
    PubMed    


  21. CHEN Z, Zhu Z, Liang W, Luo Z, et al
    Reduction of anaerobic glycolysis contributes to angiotensin II-induced podocyte injury with foot process effacement.
    Kidney Int. 2023;103:735-748.
    PubMed     Abstract available


    February 2023
  22. TUTTLE KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, et al
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.
    Kidney Int. 2023 Feb 2:S0085-2538(23)00056-X. doi: 10.1016/j.kint.2022.
    PubMed     Abstract available


  23. CAZA TN, Larsen CP
    False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus.
    Kidney Int. 2023;103:425.
    PubMed    


    January 2023
  24. FU EL, Kutz A, Desai RJ
    Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
    Kidney Int. 2023;103:30-33.
    PubMed     Abstract available


    December 2022
  25. RAYEGO-MATEOS S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, et al
    Targeting inflammation to treat diabetic kidney disease: the road to 2030.
    Kidney Int. 2022 Dec 2:S0085-2538(22)01017-1. doi: 10.1016/j.kint.2022.
    PubMed     Abstract available


  26. WU H, Humphreys BD
    Immune cell heterogeneity in a mouse model of diabetic kidney disease.
    Kidney Int. 2022;102:1215-1216.
    PubMed     Abstract available


    November 2022

  27. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2022;102.
    PubMed    


  28. ROSSING P, Caramori ML, Chan JCN, Heerspink HJL, et al
    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
    Kidney Int. 2022;102:990-999.
    PubMed     Abstract available


    October 2022
  29. BAKRIS GL, Ruilope LM, Anker SD, Filippatos G, et al
    Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2022 Oct 28. pii: S0085-2538(22)00910.
    PubMed     Abstract available


  30. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    CD248 induces a maladaptive unfolded protein response in diabetic kidney disease.
    Kidney Int. 2022 Oct 26. pii: S0085-2538(22)00904.
    PubMed     Abstract available


  31. LASSEN E, Bouchareb R, Daehn IS
    Podocyte as the link between sterile inflammation and diabetic kidney disease.
    Kidney Int. 2022;102:688-690.
    PubMed     Abstract available


    September 2022
  32. DE BOER IH, Khunti K, Sadusky T, Tuttle KR, et al
    Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
    Kidney Int. 2022 Sep 27. pii: S0085-2538(22)00634.
    PubMed     Abstract available


  33. FU J, Sun Z, Wang X, Zhang T, et al
    The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease.
    Kidney Int. 2022 Sep 12. pii: S0085-2538(22)00715.
    PubMed     Abstract available


  34. SPEER T, Schunk SJ
    Klotho in diabetic kidney disease: more than dust in the Wnt.
    Kidney Int. 2022;102:469-471.
    PubMed     Abstract available


  35. ZHAN P, Zhang Y, Shi W, Liu X, et al
    Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease.
    Kidney Int. 2022;102:546-559.
    PubMed     Abstract available


    August 2022
  36. STEFANSSON VTN, Nair V, Melsom T, Looker HC, et al
    Molecular Programs Associated with Glomerular Hyperfiltration in Early Diabetic Kidney Disease.
    Kidney Int. 2022 Aug 30. pii: S0085-2538(22)00689.
    PubMed     Abstract available


  37. XIA Y, Coates PT, Nangaku M
    How does diabetes cause susceptibility to COVID in the kidney: new clues provided by organoids.
    Kidney Int. 2022 Aug 10. pii: S0085-2538(22)00608.
    PubMed    


  38. SUZUKI Y, Kaneko H, Okada A, Matsuoka S, et al
    Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Kidney Int. 2022 Aug 4. pii: S0085-2538(22)00510.
    PubMed     Abstract available


  39. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. "Role of the macula densa sodium glucose cotransporter type 1-neuronal nitri
    Kidney Int. 2022;102:448.
    PubMed    


  40. RHEE EP
    Proteomic discovery in diabetic kidney disease-to what end?
    Kidney Int. 2022;102:236-238.
    PubMed     Abstract available


    July 2022
  41. ZENG W, Beyene HB, Kuokkanen M, Miao G, et al
    Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.
    Kidney Int. 2022 Jul 16. pii: S0085-2538(22)00536.
    PubMed     Abstract available


  42. JAGANNATHAN G, Finkielstein VA, Markowitz GS, Kudose S, et al
    Armanni-Ebstein lesion in a diabetic patient with acute tubular injury.
    Kidney Int. 2022;102:213.
    PubMed    


    June 2022
  43. SHAHZAD K, Fatima S, Khawaja H, Elwakiel A, et al
    Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease.
    Kidney Int. 2022 Jun 29. pii: S0085-2538(22)00513.
    PubMed     Abstract available


  44. TUTTLE KR, Agarwal R, Alpers CE, Bakris GL, et al
    Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease.
    Kidney Int. 2022 Jun 2. pii: S0085-2538(22)00436.
    PubMed     Abstract available



  45. Corrigendum to Fang Y, Chen B, Gong AY, et al. "The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults." Kidney Int. 2021;100:1037-1053.
    Kidney Int. 2022;101:1301-1302.
    PubMed    


    May 2022
  46. CHEN X, Tan H, Xu J, Tian Y, et al
    Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00378.
    PubMed     Abstract available


  47. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    PubMed     Abstract available


  48. KOBAYASHI H, Looker HC, Satake E, Saulnier PJ, et al
    Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kidney Int. 2022 May 23. pii: S0085-2538(22)00372.
    PubMed     Abstract available


  49. LI H, Zhao X, Zheng L, Wang X, et al
    Bruceine A protects against diabetic kidney disease via inhibiting galectin-1.
    Kidney Int. 2022 May 19. pii: S0085-2538(22)00369.
    PubMed     Abstract available


  50. NAGAI Y, Matoba K, Takeda Y, Yako H, et al
    Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism.
    Kidney Int. 2022 May 18. pii: S0085-2538(22)00370.
    PubMed     Abstract available


  51. PRUIJM M, Phan O, Zanchi A
    Metformin versus SGLT-2 inhibitors: how low can we go?
    Kidney Int. 2022;101:874-877.
    PubMed     Abstract available


  52. NISHI H
    Lay A TRAP for myeloid cell response in diabetic kidney disease.
    Kidney Int. 2022;101:872-874.
    PubMed     Abstract available


    April 2022
  53. XIE Y, E J, Cai H, Zhong F, et al
    Reticulon-1A mediates diabetic kidney disease progression through endoplasmic reticulum-mitochondrial contacts in tubular epithelial cells.
    Kidney Int. 2022 Apr 22. pii: S0085-2538(22)00336.
    PubMed     Abstract available


    March 2022
  54. CORREMANS R, Neven E, Maudsley S, Leysen H, et al
    Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
    Kidney Int. 2022 Mar 7. pii: S0085-2538(22)00176.
    PubMed     Abstract available


  55. PRESSLY JD, Ge M, Fornoni A
    LPCing through the nephron accelerates diabetic kidney disease.
    Kidney Int. 2022;101:454-456.
    PubMed     Abstract available


    February 2022
  56. HARUHARA K, Suzuki T, Wakui H, Azushima K, et al
    Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization.
    Kidney Int. 2022 Feb 28. pii: S0085-2538(22)00161.
    PubMed     Abstract available


  57. SASAKO T, Yamauchi T
    Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.
    Kidney Int. 2022;101:222-224.
    PubMed     Abstract available


  58. XU Y, Fu EL, Clase CM, Mazhar F, et al
    GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Kidney Int. 2022;101:360-368.
    PubMed     Abstract available


  59. HONG Q, Cai H, Zhang L, Li Z, et al
    Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich -2 glycoprotein-1.
    Kidney Int. 2022;101:299-314.
    PubMed     Abstract available


    January 2022
  60. HASEGAWA S, Nangaku M
    SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
    Kidney Int. 2022;101:20-22.
    PubMed     Abstract available


    December 2021

  61. Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314-318.
    Kidney Int. 2021;100:1351-1352.
    PubMed    



  62. Corrigendum to Wu L, Liu C, Chang D-Y, et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney Int. 2021;100:107-121.
    Kidney Int. 2021;100:1349-1350.
    PubMed    


    November 2021
  63. YOSHIOKA K, Hirakawa Y, Kurano M, Ube Y, et al
    Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.
    Kidney Int. 2021 Nov 29. pii: S0085-2538(21)01084.
    PubMed     Abstract available


  64. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Role of the macula densa sodium glucose cotransporter type 1-nitric oxide synthase 1-tubuloglomerular feedback pathway in diabetic hyperfiltration.
    Kidney Int. 2021 Nov 26. pii: S0085-2538(21)01078.
    PubMed     Abstract available


  65. ANSERMET C, Centeno G, Bignon Y, Ortiz D, et al
    Dysfunction of the circadian clock in the kidney tubule leads to enhanced kidney gluconeogenesis and exacerbated hyperglycemia in diabetes.
    Kidney Int. 2021 Nov 24. pii: S0085-2538(21)01081.
    PubMed     Abstract available


  66. KAESLER N, Schreibing F, Speer T, Puente-Secades S, et al
    Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.
    Kidney Int. 2021 Nov 10. pii: S0085-2538(21)01056.
    PubMed     Abstract available


  67. KUME S
    Ketone bodies: back to a place in the sun.
    Kidney Int. 2021;100:976-978.
    PubMed     Abstract available


    October 2021
  68. MOLLER-HACKBARTH K, Dabaghie D, Charrin E, Zambrano S, et al
    Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-kappaB signaling pathway.
    Kidney Int. 2021;100:809-823.
    PubMed     Abstract available


    September 2021
  69. HEERSPINK HJ, Cherney D, Postmus D, Stefansson BV, et al
    A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00865.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.